Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

High Ambitions For EU DARWIN Platform After Delivery Of First RWE Studies

Executive Summary

Within one year of its establishment, DARWIN EU has started reaping benefits for EU drug regulators commissioning studies using real-world data to better understand diseases, populations and the uses and effects of medicines. The studies can be performed faster, cheaper and at increased capacity.

You may also be interested in...



EU Health Experts On How ‘Optimization’ Could Improve Benefit Of New Cancer Drugs

EU health policy experts including the European Medicines Agency’s Emer Cooke discuss ways to optimize the use of innovative cancer medicines, given that many new drugs fail to offer notable clinical benefits compared to existing therapies.

EMA Makes Progress On Real-World Evidence ‘Use Cases’ With HTA Bodies & Payers

The European Medicines Agency is looking at how it can generate real-world evidence on multiple myeloma and non-small cell lung cancer using its new DARWIN EU platform so that the outcomes can also be of use for health technology assessment bodies and payers.

RWE Studies To Hit 100+ Per Year In Europe By 2025

The EU’s big data steering group has laid out some ambitious proposals for integrating real-world evidence into regulatory decision making, as well as plans for ongoing engagement on the use and analysis of RWE with industry and other stakeholders.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS147968

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel